# A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

> **NCT02496221** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Albiglutide 50 mg
- **DRUG:** Placebo
- **DRUG:** CCK (Kinevac)

## Key facts

- **NCT ID:** NCT02496221
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-11
- **Primary completion:** 2015-10-13
- **Final completion:** 2015-10-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496221, "A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02496221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*